SynAct Pharma AB Cash Flow-to-Debt Ratio
SynAct Pharma AB cash flow-to-debt ratio. SynAct Pharma AB (SYNACT) has a Cash Flow-to-Debt Ratio of -0.75x as of March 2026, meaning its operating cash flow of Skr-32.95 Million could theoretically repay -1% of its total liabilities (Skr44.13 Million) in one year. See SYNACT FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SynAct Pharma AB (2016–2025)
Cash flow-to-debt ratio of SynAct Pharma AB from 2016 to 2025. Historical debt coverage capacity for SynAct Pharma AB across 10 annual periods. Check SynAct Pharma AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SynAct Pharma AB Cash Flow-to-Debt Ratio by Year (2016–2025)
SynAct Pharma AB cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for SynAct Pharma AB. For the full cash flow conversion analysis, see SynAct Pharma AB cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.94x | Skr-97.33 Million | Skr50.23 Million | ▼ -22.4% |
| 2024 | -1.58x | Skr-89.20 Million | Skr56.35 Million | ▲ +18.1% |
| 2023 | -1.93x | Skr-100.18 Million | Skr51.83 Million | ▲ +73.6% |
| 2022 | -7.31x | Skr-117.56 Million | Skr16.08 Million | ▼ -96.9% |
| 2021 | -3.71x | Skr-65.00 Million | Skr17.50 Million | ▲ +36.0% |
| 2020 | -5.81x | Skr-33.24 Million | Skr5.72 Million | ▼ -271.3% |
| 2019 | -1.56x | Skr-16.12 Million | Skr10.31 Million | ▲ +76.0% |
| 2018 | -6.52x | Skr-24.21 Million | Skr3.72 Million | ▲ +12.4% |
| 2017 | -7.44x | Skr-17.20 Million | Skr2.31 Million | ▼ -76.3% |
| 2016 | -4.22x | Skr-14.73 Million | Skr3.49 Million | — |